These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 35469393)

  • 81. Use of Utility and Disability Weights in Economic Evaluation of Pediatric Vaccines.
    Neppelenbroek NJM; de Wit GA; Dalziel K; Devlin N; Carvalho NI
    Value Health; 2023 Jul; 26(7):1098-1106. PubMed ID: 36967026
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Perspective and Costing in Cost-Effectiveness Analysis, 1974-2018.
    Kim DD; Silver MC; Kunst N; Cohen JT; Ollendorf DA; Neumann PJ
    Pharmacoeconomics; 2020 Oct; 38(10):1135-1145. PubMed ID: 32696192
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Economic evaluation using dynamic transition modeling of ebola virus vaccination in lower-and-middle-income countries.
    Obeng-Kusi M; Habila MA; Roe DJ; Erstad B; Abraham I
    J Med Econ; 2021 Nov; 24(sup1):1-13. PubMed ID: 34866541
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Is implementation of the 2013 Australian treatment guidelines for posttraumatic stress disorder cost-effective compared to current practice? A cost-utility analysis using QALYs and DALYs.
    Mihalopoulos C; Magnus A; Lal A; Dell L; Forbes D; Phelps A
    Aust N Z J Psychiatry; 2015 Apr; 49(4):360-76. PubMed ID: 25348698
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Effects of geographic and economic heterogeneity on the burden of rotavirus diarrhea and the impact and cost-effectiveness of vaccination in Pakistan.
    Rheingans R; Anderson JD; Bagamian KH; Laytner LA; Pecenka CJ; Gilani SSA; Ahmed M
    Vaccine; 2018 Dec; 36(51):7780-7789. PubMed ID: 30007826
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
    Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
    Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Introducing Rotavirus Vaccination in Nigeria: Economic Evaluation and Implications.
    Okafor CE
    Pharmacoecon Open; 2021 Sep; 5(3):545-557. PubMed ID: 33410094
    [TBL] [Abstract][Full Text] [Related]  

  • 89. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].
    Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E
    Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Cost-utility analysis of adjunct repetitive transcranial magnetic stimulation for treatment resistant bipolar depression.
    Chatterton ML; Lee YY; Le LK; Nichols M; Carter R; Berk M; Mihalopoulos C
    J Affect Disord; 2024 Jul; 356():639-646. PubMed ID: 38657770
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Cost per DALY averted in low, middle- and high-income countries: evidence from the global burden of disease study to estimate the cost-effectiveness thresholds.
    Daroudi R; Akbari Sari A; Nahvijou A; Faramarzi A
    Cost Eff Resour Alloc; 2021 Feb; 19(1):7. PubMed ID: 33541364
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Scaling up antivenom for snakebite envenoming in the Brazilian Amazon: a cost-effectiveness analysis.
    Zimmerman A; Monteiro W; Nickenig Vissoci JR; Smith ER; Rocha T; Sachett J; Wen FH; Staton C; Gerardo CJ; Ogbuoji O
    Lancet Reg Health Am; 2024 Jan; 29():100651. PubMed ID: 38124996
    [TBL] [Abstract][Full Text] [Related]  

  • 93. The potential cost-effectiveness of HPV vaccination among girls in Mongolia.
    Luvsan ME; Vodicka E; Jugder U; Tudev U; Clark A; Groman D; Otgonbayar D; Demberelsuren S; LaMongtagne DS; Pecenka C
    Vaccine X; 2022 Aug; 11():100161. PubMed ID: 35509519
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Investing in a global pooled-funding mechanism for late-stage clinical trials of poverty-related and neglected diseases: an economic evaluation.
    Zimmerman A; Diab MM; Schäferhoff M; McDade KK; Yamey G; Ogbuoji O
    BMJ Glob Health; 2023 May; 8(5):. PubMed ID: 37247874
    [TBL] [Abstract][Full Text] [Related]  

  • 95. The effect of medical innovation on the cost-effectiveness of Covid 19-related policies in the United States using a SIR model.
    Atherly AJ; van den Broek-Altenburg EM
    BMC Health Serv Res; 2023 Apr; 23(1):372. PubMed ID: 37072753
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Cost Utility of Supporting Family-Based Care to Prevent HIV and Deaths among Orphaned and Separated Children in East Africa: A Markov Model-Based Simulation.
    Wilson-Barthes M; Braitstein P; DeLong A; Ayuku D; Atwoli L; Sang E; Galárraga O
    MDM Policy Pract; 2022; 7(2):23814683221143782. PubMed ID: 36601384
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Cost-Effectiveness of Four Tobacco Control Interventions in Mongolia.
    Tuvdendorj A; Feenstra T; Buskens E
    Nicotine Tob Res; 2023 Sep; 25(11):1719-1726. PubMed ID: 37478493
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Contextualization of cost-effectiveness evidence from literature for 382 health interventions for the Ethiopian essential health services package revision.
    Hailu A; Eregata GT; Yigezu A; Bertram MY; Johansson KA; Norheim OF
    Cost Eff Resour Alloc; 2021 Sep; 19(1):58. PubMed ID: 34521437
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Is the Choice of Cost-Effectiveness Threshold in Cost-Utility Analysis Endogenous to the Resulting Value of Technology? A Systematic Review.
    Padula WV; Chen HH; Phelps CE
    Appl Health Econ Health Policy; 2021 Mar; 19(2):155-162. PubMed ID: 32812212
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Can cost-effectiveness results be combined into a coherent league table? Case study from one high-income country.
    Wilson N; Davies A; Brewer N; Nghiem N; Cobiac L; Blakely T
    Popul Health Metr; 2019 Aug; 17(1):10. PubMed ID: 31382954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.